Artificial Intelligence Will Make the Health System Unrecognizable... and That's Good

For hundreds of years, all sick, injured, and dying people have been brought together in one place to provide care for lack of resources: the hospital. Nowadays, it is less the resources that are lacking than the will to change the ways of doing things to offer tailor-made care where the patients are.

But that is changing. In recent years, most players in the health system with psych evaluation near me seem to have understood that they will not be able to resist the changes caused by new technologies in general, and artificial intelligence, for very long. The opening is therefore very real.

In the technological world, many companies are putting pressure on this industry, and for good reason: its value in 2017 was US$800 billion, and spending is growing, so much so that we predict healthcare worth US$1.35 trillion by 2025.

Diagnose cancer in six seconds, not six months

From multinationals like Apple and Amazon to startups like Imagia and Arctic Fox AI, it should come as no surprise that everyone wants their piece of the pie. There is a business logic behind this interest, but in some cases, it goes far beyond profits and revenue. “We especially want to have a beneficial impact on people’s health,” explains Alexandre Le Bouthillier, co-founder of Imagia, who has just inaugurated his offices in the same building as his colleague Element AI, in Mile-Ex.

Alexandre Le Bouthillier and Jean-François Gagne, who directs Element AI, know each other well, having founded together, then sold the company Planora, before plunging each their way into artificial intelligence.

Cancer that led to the death of Claude Le Bouthillier, Alexandre’s father, but also an Acadian author recognized across the country, in 2016, will have, so to speak, defined Imagia’s mission. When you have cancer, apparently you are prepared to do a great deal to cure it, but people with cancer will also frequently want to give back, during a discussion with Les Affaires, earlier. this week.

Paying it forward is a way of presenting the technology developed by the Montreal startup of around fifty employees. She has designed a technique for recognizing almost instantaneous benign and malignant polyps by image, accelerating the detection (and then the treatment) of colon cancer. Since this technique is based on a vast amount of data from various other cases, it can be said that all these people who have been screened have, so to speak, contributed to refining this solution.

The technology has pleased Olympus, the biggest player in medical imaging, which has integrated this tool into its systems. It took us eighteen months to create and then promote a solution which, under typical circumstances, can take 10 to 12 years before getting the consent of medical authorities like the FDA, in the United States. With this system, it is like considering the best two or three medical experts in the world and placing one in every hospital on the earth.

Single AI, Multiple Applications

Together with Yoshua Bengio, the star professor of AI in Montreal, the company saw fit to expand its data analysis method so that it could be applied to other diseases and other issues in the field of health. This made it possible to quickly expand its field of action to lung cancer, and certain other diseases, such as Alzheimer’s.

For Imagia, this is only the beginning

We are creating ‘AI biomarkers’, which link two sources of data to detect and then identify the signs of a serious disease. We want to go as far as forecasting the right therapy to apply to make sure of the treatment. For example, AI could make it easier to choose between two treatments that only work 30 percent of the time, so that you hit the right 30 percent.

These “AI biomarkers” are based on an analysis of massive, but selective data (“we don’t do “big data”, but “right data””) carried out in the health establishment from the data that he owns. No information leaves its servers, guaranteeing the security of the operation.

What Imagia does from there is to offer these AI biomarkers to OEMs and manufacturers of medical solutions that are already present in the healthcare system. What makes it feasible to act swiftly is that we place ourselves as a discriminator, rather than a competitor. We offer added value to manufacturers.

On the way to personalized medicine… and more affordable

What Imagia does is spectacular. Accelerating the very early detection of a serious illness saves lives. We are far at the other end of the spectrum of more “playful” technologies, such as these exercise bracelets that we are trying to present as medical devices because they provide the heart rate of their users.

But clearly, the objective is the same: medicine and health are less and less a big center of centralized and uniform services. New technologies can decentralize some of the tasks reserved for hospitals, such as the early detection of serious illnesses, and can help reduce system costs. Imagia’s technology can avoid sending samples to specialized labs that take months to analyze, costing the San Diego psychological healthcare system more than a billion dollars.

Even insurers are beginning to see the virtues of this technological shift. Soon, you will be offered to wear a connected watch in exchange for a reduction in your life insurance premium.

Leave a Reply

Your email address will not be published. Required fields are marked *